The Heart Failure Association, European Association of Cardiovascular Imaging, European Heart Rhythm Association and European Association of Percutaneous Cardiovascular Interventions all collaborated on the position statement.
New research out of Duke University provides a fresh perspective on the connection between prior hospitalizations for heart failure and all-cause mortality.
The study, published in Hypertension, included data from more than 8,000 U.S. veterans.
The findings, published in JAMA Cardiology, confirm that dapagliflozin is a safe, effective treatment option for patients with heart failure with reduced ejection fraction.
The study’s authors tracked data from more than 2,800 patients with HFrEF, sharing their findings in JAMA Cardiology.
The guidance, an update to a similar document from 2005, was published in Circulation: Cardiovascular Quality and Outcomes.
Tracking a patient's longitudinal strain and circumferential strain may improve the ability to predict their risk of heart failure later in life.
The company also hopes to launch an early feasibility study in the United States in the near future.
As more and more Americans receive their COVID-19 vaccine, heart failure patients and heart transplant recipients may have specific questions about how they should proceed.
After tracking data for nearly 800 professional athletes, the researchers found that no adverse cardiac events were reported after a mild or asymptomatic COVID-19 infection.
Current heart failure definitions are "ambiguous and lack standardization," the groups wrote.
This is a Class I recall, which means using the device can lead to serious injury or death.